In 2023, colorectal cancer (CRC) is the third most diagnosed malignancy and the third
leading cause of cancer death worldwide. At the time of the initial visit, 20% of patients …

Colorectal cancer (CRC) is the third most diagnosed malignancy and a major leading cause
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …

Colorectal cancer (CRC) is one of the most lethal and common malignancies in the world.
Chemotherapy has been the conventional treatment for metastatic CRC (mCRC) patients …

The development of monoclonal antibodies (mAbs) cetuximab and panitumumab, which
target the transmembrane protein epidermal growth factor receptor (EGFR), mark a major …

In the last two decades, great efforts have been made in the treatment of metastatic
colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs …

As survival has improved for patients with metastatic colorectal cancer (mCRC), there is an
increasing need for effective and well-tolerated third-line and subsequent-lines of treatment …

Simple Summary Metastatic colorectal cancer (mCRC) accounts for relevant cancer-related
morbidity and mortality. Novel investigations have reshaped the molecular makeup of …

Colorectal cancer (CRC) represents 10% of all cancer types, making it the third leading
cause of cancer-related deaths globally. Metastasis is the primary factor causing mortality in …

Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of
metastatic CRC (mCRC) remains poor. Recent advancements in translational research have …

Emergence of acquired resistance limits the efficacy of the anti-EGFR therapies cetuximab
and panitumumab in metastatic colorectal cancer. In the last decade, preclinical and clinical …